United Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,256 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,256 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $122.98, for a total value of $154,462.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 119.78 on Tuesday. The firm has a market cap of $5.20 billion, a price-to-earnings ratio of 13.89 and a beta of 1.50. The firm has a 50-day moving average price of $122.99 and a 200-day moving average price of $126.06. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.42 EPS. Analysts predict that United Therapeutics Corporation will post $10.60 EPS for the current fiscal year.

WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/17/martine-a-rothblatt-sells-1256-shares-of-united-therapeutics-corporation-uthr-stock.html.

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of United Therapeutics Corporation by 3.3% in the second quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock worth $635,330,000 after acquiring an additional 155,349 shares in the last quarter. FMR LLC lifted its stake in shares of United Therapeutics Corporation by 2.8% in the second quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock worth $551,980,000 after acquiring an additional 116,062 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of United Therapeutics Corporation by 0.7% in the second quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock worth $494,291,000 after acquiring an additional 25,047 shares in the last quarter. State Street Corp lifted its stake in shares of United Therapeutics Corporation by 0.9% in the second quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock worth $261,345,000 after acquiring an additional 17,179 shares in the last quarter. Finally, Palo Alto Investors LLC lifted its stake in shares of United Therapeutics Corporation by 0.8% in the first quarter. Palo Alto Investors LLC now owns 1,883,315 shares of the biotechnology company’s stock worth $254,963,000 after acquiring an additional 14,500 shares in the last quarter.

UTHR has been the subject of a number of recent analyst reports. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. Finally, UBS AG reiterated a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Five investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics Corporation has a consensus rating of “Hold” and an average target price of $132.09.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply